Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer

Figures & data

Table 1. Patient characteristics.

Characteristics	N (%)
Patients enrolled	44
Gender, n (%)
Males	32 (73%)
Females	12 (27%)
Median age (range), years	66 (35-86)
Baseline ECOG PS, n (%)
0–1	13 (30%)
≥2	31 (70%)
Histology, n (%)
Adenocarcinoma	30 (68%)
Squamous cell carcinoma	14 (32%)
EGFR status, n (%)
Mutation	13 (30%)
Wild type/unknown	31 (70%)
Line of anlotinib
Third line	26 (59%)
Further line	18 (41%)
Prior chemotherapy
Used antitumor angiogenesis	21 (48%)
Unused antitumor angiogenesis	23 (52%)
Prior immunotherapy
Yes	7 (16%)
No	37 (84%)

Abbreviation: ECOG PS, eastern cooperative oncology group performance status; EGFR, epidermal growth factor receptor.

Table 2. Treatment efficacy in patients with anlotinib.

Clinical outcomes	All (n = 44)
Response rate
CR	0
PR	2 (5%)
SD	37 (84%)
PD	5 (11%)
PFs (months)	4.0 (2.92–5.08)
OS (months)	8.5 (7.12–9.88)
DCR	89%
ORR	5%

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival; DCR, disease control rate; ORR, objective response rate.

Figure 1. Prognostic factors associated with the progression-free survival after the administration of anlotinib. HR, hazard ratio; CI, confidence interval; P, p value.

Figure 2. Prognostic factors associated with the overall survival after the administration of anlotinib. HR, hazard ratio; CI, confidence interval; P, p value.

Figure 3. Progression-free survival and overall survival of patients who treated with anlotinib. (a) The median PFS, 4.0 months, 95% CI 2.92–5.08; (b) the median OS, 8.2 months, 95% CI 7.12–9.88.

Table 3. Drug reactions in the anlotinib.

Adverse drug reaction	1–2 grade [N (%)]	3–4 grade [N (%)]
Fatigue	26 (59%)	2 (5%)
Anorexia	26 (59%)	1 (2%)
Hand–foot syndrome	18 (41%)	1 (2%)
Diarrhea	12 (27%)	0 (0%)
Oral mucositis	6 (14%)	0 (0%)
Vomiting	3 (7%)	0 (0%)
Hypertension	20 (45%)	2 (5%)
Sinus tachycardia	4 (9%)	0 (0%)
Rash	6 (14%)	0 (0%)
Proteinuria	1 (2%)	0 (0%)
Hematuria	2 (5%)	0 (0%)
Thrombocytopenia Leukopenia Anemia	3 (7%) 5 (11%) 4 (9%)	0 (0%) 0 (0%) 0 (0%)
Elevated liver enzymes	10 (23%)	0 (0%)
Increased urea nitrogen High uric acid	2 (5%) 3 (7%)	0 (0%) 0 (0%)
Abnormal blood coagulation	6 (14%)	0 (0%)

Data availability statement

All data are available by contacting correspondence authors: via: [email protected]